Edge Therapeutics IPO

9/30/2015

IPO

$80,300,000

We estimate that our net proceeds from the sale of the shares of common stock in this offering will be approximately $76.3 million, assuming an initial public offering price of $15.00 per share, the midpoint of the price range set forth on the cover page of this prospectus, and after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us. If the underwriters exercise in full their over-allotment option, we estimate that our net proceeds from this offering will be approximately $88.1 million, after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us.We intend to use the net proceeds to us from this offering as follows: approximately $50 million to fund our planned Phase 3 clinical program (including costs associated with the NEWTON trial and manufacturing scale-up) for EG-1962 for the management of aSAH through read out of top-line data; approximately $3 million to fund our dev

Publicly-held

Biopharmaceutical

300 Connell Dr. 4000
Berkeley Heights, NJ 07922
USA

Undisclosed

Edge Therapeutics, a pharmaceutical company, transforms FDA-approved drugs into therapies that address unmet acute neurological conditions.